OmniAb, Inc. (OABI)
NASDAQ: OABI · Real-Time Price · USD
3.610
+0.190 (5.56%)
Aug 13, 2026, 10:56 AM EDT - Market open
OmniAb Revenue
OmniAb had revenue of $13.42M in the quarter ending June 30, 2026, with 244.24% growth. This brings the company's revenue in the last twelve months to $38.46M, up 67.01% year-over-year. In the year 2025, OmniAb had annual revenue of $18.67M, down -29.27%.
Revenue (ttm)
$38.46M
Revenue Growth
+67.01%
P/S Ratio
12.93
Revenue / Employee
$432,101
Employees
89
Market Cap
524.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.67M | -7.73M | -29.27% |
| Dec 31, 2024 | 26.39M | -7.77M | -22.75% |
| Dec 31, 2023 | 34.16M | -24.91M | -42.17% |
| Dec 31, 2022 | 59.08M | 24.33M | 70.02% |
| Dec 31, 2021 | 34.75M | 11.48M | 49.34% |
| Dec 31, 2020 | 23.27M | 4.95M | 27.02% |
| Dec 31, 2019 | 18.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 180.25M |
| Scribe Therapeutics | 36.28M |
| Prelude Therapeutics | 16.72M |
| Evommune | 10.00M |
| Ovid Therapeutics | 7.12M |
| ProKidney | 818.00K |
| Inhibikase Therapeutics | 1.00 |
OABI News
- 3 days ago - OmniAb Slides: Corporate presentation - Filings
- 6 days ago - OmniAb reports Q2 EPS (5c), consensus (13c) - TheFly
- 6 days ago - OmniAb raises FY26 revenue view to $32M-$36M from $28M-$33M - TheFly
- 6 days ago - OmniAb Earnings Call Transcript: Q2 2026 - Transcripts
- 6 days ago - OmniAb Slides: Q2 2026 - Filings
- 6 days ago - OmniAb Quarterly report: Q2 2026 - Filings
- 6 days ago - OmniAb Earnings release: Q2 2026 - Filings
- 6 days ago - OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights - Business Wire